⏱ News is delayed by 15 minutes. Sign in for real-time access.
Sign in
INMB News
INmune Bio Inc. Common stock
INmune Bio Inc. to Report Year End 2025 Financial Results and Provide Corporate Update on Monday, March 30th.
globenewswire.com
INMB
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
globenewswire.com
INMB
Form 8-K
sec.gov
INMB
Form 8-K
sec.gov
INMB
INmune Bio to Detail XPro1595 Registrational Strategy in Upcoming Alzheimer’s Webinar
globenewswire.com
INMB
Form 8-K
sec.gov
INMB
INmune Bio Announces Upcoming Webinar to Present New Clinical Data on CORDStrom™ for RDEB
globenewswire.com
INMB
IPSC-derived NK Cells Clinical Trial Pipeline Gains Momentum: 12+ Companies Lead the Charge in Pioneering New Treatments | DelveInsight
globenewswire.com
FATE
INDP
AMGN
NKTR
IBIO
TAK
SNY
INMB
CLMT
VERX
GTBP
BHVN
CHRS
GSK
BMY
MRK
ABBV
AZN
GILD
LLY
KYMR
REGN
SPRY
INmune Bio Announces FDA Alignment on Integrated Phase 2b/3 Registration Pathway for XPro1595 in Early Alzheimer’s Disease
globenewswire.com
INMB
INmune Bio Advances CORDStrom™ Towards UK Marketing Authorization in RDEB
globenewswire.com
INMB